Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech for less than a buck. -- Ignore unavailable to you. Want to Upgrade?

To: Cheryl Galt who wrote (499)	3/19/2000 7:39:00 PM
From: RWReeves	Read Replies (1) \| Respond to of 743

Cheryl, That's an admirable trading strategy and one I wish I could stick to as well. VVUS was a bit of luck as to timing. A shame it lost a fair amount of ground from the intraday high, but with this incredible volume, we've certainly built a resistive base on the way up. I'll hold it until they get acquired- too good a fit for Pharma product lines, make a a great call audience synergy for you know who.My target for this is still a ways off. SPGNA, lots of fun and dangerous as a box full of razor blades. Trying to accumulate long term but the bad boys keep spiking it. If I had the bucks I'd just buy them out and run it myself. RFC has tremendous potential-I worked in this area in 88/89.Ah, memories. Right on with CEGE, as I mentioned to Mike the ABGX windfall is nice but I like the fact that GENZ DD'd it and made the move. Really validates the technology value for me. Not LTAB but a Bargain. BTRN, I'm not the huge fan of pork I once was. There are lots of other transplant modalities shaping up and BTRN may be too focussed to make the transition. Look at CERS for some interesting discussion, use 10K wizard and ignore the (nice in it's own right) blood supply safety programs and go for transplant stuff. You'll see what I mean. Plus there is a private company that will soon go publicwith good transplant results. Lots outside the US that isn't making it to the journals here either. That's not to say BTRN isn't a good bet- short term may engage a NERX type spike on news. Just perspective. Hard to go wrong with pharma and CROs long term. They shall rise again. RWR